← Eichor
Condition: Advanced Solid Tumors With Kras G12C Mutations Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Solid Tumors With Kras G12C Mutations

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harbor
Phase 2 · 31 location(s) · Allist Pharmaceuticals, Inc. · NCT06008288A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Frontier Medicines Corporation · NCT06244771A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Phase 2 · 11 location(s) · Amgen · NCT07172919Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/Phase 2 · 93 location(s) · Revolution Medicines, Inc. · NCT06162221Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agen
Phase 1/Phase 2 · 7 location(s) · Novartis Pharmaceuticals · NCT07468071A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
Phase 1/Phase 2 · 32 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06959615Phase 1/2 Study of HS-10370 in Patients with Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT05367778Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
Phase 1/Phase 2 · 27 location(s) · Allist Pharmaceuticals, Inc. · NCT05288205JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Phase 1/Phase 2 · 4 location(s) · Jacobio Pharmaceuticals Co., Ltd. · NCT06973564A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
Phase 1/Phase 2 · 52 location(s) · D3 Bio (Wuxi) Co., Ltd · NCT05410145A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specifi
Phase 1 · 10 location(s) · Bayer · NCT06659341A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour
Phase 1 · 1 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT06383871A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced
Phase 1 · 11 location(s) · Kumquat Biosciences Inc. · NCT06720987A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Phase 1 · 20 location(s) · Astellas Pharma Inc · NCT07094204
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.